Do You Need a License to Sell Peptides in South Carolina?

Almost certainly you need something — but it is rarely one license, and it is usually not the license people picture. Any business selling a product in South Carolina sits inside a general commercial layer: entity formation, state tax registration, and in many counties and municipalities a local business license. That layer applies whether you sell research compounds, candles, or industrial fasteners. The harder questions sit above it: how the material you hold is classified, whether distribution of that class of material triggers its own state or federal registration, and whether your sales stay inside the research-use-only lane where nothing is offered, labeled, or marketed for human use. Those questions are answered by your attorney and the relevant South Carolina agencies reading your actual model — not by an article, including this one. What follows is informational only and is not legal advice.

Three questions compressed into one

When an operator asks whether a license is required, they are usually stacking three separate inquiries on top of each other and hoping for a single yes or no.

The first is commercial authorization. Are you a registered entity? Are you registered for sales and use tax where you have nexus? Does your municipality or county require a local business license for a product-sales operation at your address? This layer is procedural, well documented, and the same for most product categories. It is also the only layer where the answer is genuinely close to a form you file.

The second is product classification. This is where operators get into trouble, because classification is not something you assert on a website — it is something a regulator infers from the totality of your conduct. Labeling, marketing copy, the questions your sales team answers, what your packaging shows, whether you pair compounds with anything that implies administration, and how your customers describe what they bought all feed into how the material is characterized. Two businesses can hold identical vials and occupy entirely different regulatory positions because one of them wrote its landing page as though the compound were a therapy.

The third is distribution licensure. Separate from general business registration, there are state and federal frameworks that govern who may distribute certain regulated categories of product, with their own applications, facility requirements, recordkeeping obligations, and inspection regimes. Whether any of those frameworks reaches your operation depends entirely on the classification question above. Getting question two wrong is what makes question three expensive.

A fourth question applies if licensed professionals work inside your business: scope of practice. That is not a peptide question at all. It belongs to whichever South Carolina professional board issued that individual's license, and the answer varies by profession, by supervision arrangement, and sometimes by the specific facts of a given arrangement. Ask the board, in writing, and keep the answer.

Where each answer actually comes from

One reason this topic generates so much bad information online is that people ask the wrong body. A county business-license clerk cannot tell you how your inventory is classified. Your supplier cannot tell you what your professional board permits. Sort the questions by who owns them before you spend money on any of them.

Notice that only the first row is answered by a government form. The rest are answered by analysis, by boards, or by documentation you either have or do not have. Budget accordingly: the filing fees are the cheap part.

What research-use-only actually constrains

Research-use-only is a discipline, not a disclaimer. Operators who treat it as a footnote at the bottom of a product page have not adopted it; they have decorated around it. Adopting it means the entire commercial surface of your business is consistent with the claim.

In practice that means product pages that describe compound science rather than outcomes. It means never publishing dosing, administration guidance, or protocols, and never letting a support inbox supply them informally. It means avoiding any pairing of compounds with materials that imply a route of administration — the bundle itself becomes a claim. It means that when research is genuinely relevant, it is framed honestly: studies indicate, research suggests, early work has examined. It means your marketing never describes what a person experienced.

It also means being clear about who you sell to and what they represent when they buy. A meaningful portion of enforcement risk in this category has historically attached to how products were promoted rather than to the molecules themselves. That is a durable pattern worth understanding, and it is the reason a careful supplier will scrutinize your marketing before your credit application.

If your intended model does not survive research-use-only framing — if the business only works when the compound is described as a therapy — that is not a supplier problem or a licensing problem. That is a model problem, and it is worth discovering before inventory is on your shelves rather than after.

Diligence runs both directions

The licensing question and the sourcing question are the same question wearing different clothes. Whatever position your counsel helps you take, you can only defend it with documentation you actually hold. That documentation comes from your supplier.

Ask for a certificate of analysis tied to the specific lot you will receive, not a generic sample document from an unrelated batch. Confirm the analytical method behind the purity figure — HPLC is the working standard for identity and purity in this category, and a supplier who cannot name the method is telling you something. Ask whether COAs are published where anyone can check them or whether they are furnished on request, and note that some operations sell testing documentation as a separate line item, which is a pricing signal worth reading.

Ask where fulfillment originates and what the realistic transit picture looks like, because inventory that arrives unpredictably becomes a customer-service problem you will own. Ask how pricing tiers are structured and whether the structure is published or negotiated case by case behind a login. Hidden pricing is not automatically a red flag, but it does make it impossible to model your own costs before you commit, and it tends to correlate with programs that treat small accounts as afterthoughts.

Finally, ask what happens when a lot fails testing or a shipment is disputed. A supplier's answer to that question tells you more about the relationship than any of the marketing on the front of the site. On margins, markups, and how long it takes an account to pull its weight, be skeptical of anyone who quotes you a number: those outcomes vary widely with volume, category mix, and how you sell, and a confident range from a vendor is a sales tool rather than a forecast.

Questions to put in front of counsel before your first order

Go into the conversation with specifics, not a general worry. A short, concrete list gets you a usable answer for a fraction of the time a vague one costs.

Bring your actual draft labeling and website copy, not a description of it. Bring the compound list you intend to carry and the categories they fall into. Bring your customer definition — who buys, what they represent at checkout, and how you verify it. Bring your storage and recordkeeping plan, including how you will trace a specific unit back to a specific lot and its COA. Bring your professional-license picture: who in the business holds one, and what they will and will not do. And ask directly which South Carolina agency, if any, has jurisdiction over your specific model, and whether counsel recommends seeking written guidance from that agency rather than relying on interpretation.

Then document the answer and revisit it whenever your model changes. Adding a category, changing your customer definition, or rewriting your marketing can move you across a line that did not previously apply to you.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built for business buyers — med spas, clinics, telehealth operations, and resellers stocking a catalog. The program is structured around documentation, because documentation is what a buyer in this category actually needs.

Every compound is tested to 99%+ HPLC purity, and every batch runs through a fixed testing panel rather than a spot check on selected lots. Certificates of analysis are publicly verifiable — you can review the lab results yourself before you place an order, and so can anyone auditing your file. They are not withheld behind a sales conversation and not sold as an add-on. Fulfillment ships from within the US in 5–7 days, which makes inventory planning a calculation rather than a guess.

The wholesale application is three steps and does not require a discovery call to see pricing. The catalog spans the categories most operators build around, including the popular peptides most accounts start with before broadening. Every compound is research use only, is not an FDA-approved drug, and is never offered or described for human consumption — that framing is not negotiable at the account level, and a partner whose marketing conflicts with it is not a fit for the program.

If your counsel has confirmed your model and you are ready to source against documentation you can actually show someone, the Wholesale Partner Program application is the next step. It takes a few minutes, and approval is based on your business, not on how large your first order is.

For more on the general framework, see do you need a license to sell peptides, review the wholesale peptides program, or apply for a wholesale account.